I agree, but I do think, assuming Hemaxellerate trials go well and it is spun off to a pharma company, that we could see this go to 40-50 cents with the gene silencing probably about to initiate phase 1 of their trials -- I don't think it'd be a sustainable level, but just based on pure hysteria/speculation alone. Not to mention that hemaxellerate would provide a revenue stream that would minimize/eliminate the need to dilute.